PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Amrita Barua, Samrat T. Kundu, Sofia Garza, Jared J. Fradette, Bhagya Shree Choudhary, David H. Peng, Lixia Diao, Jing Wang, Don Lynn Gibbons
This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.
bioRxiv · Dec 25, 2025 · PreprintCancer Biology